Clinical Trials Sponsored by Lingyu Luo

Total 1196 results

Lingyu Luo

Unknown

Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin

Non-squamous Non-small Cell Lung Cancer
Luo Dingcun

Not yet recruiting

Clinical Study of Ultrasonic Artificial Intelligence and Fine Needle Aspiration in Qualitative Diagnosis of Thyroid Nodules

Thyroid Nodule
Ailin Luo

Recruiting

The Safety of Etomidate - Propofol Mixture vs Propofol in Total Intravenous Anesthesia During Abdominal Surgery

Hypotension | Etomidate

China
Luo Dingcun

Unknown

Protein Classifier for Thyroid Indeterminate Nodules

Thyroid Nodule

China
Xiaoping Luo

Recruiting

Long-term Efficacy and Safety Evaluation of Growth Hormone in Children in China(CGLS)

Childhood Short Stature

China
Wen Luo

Completed

Radiographic Evaluation of a Star-shaped Incision Technique

Implant | Thin-gingiva | Clinical and Radiographic Effect | Thick-gingiva

China
Luo Cong

Completed

The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma

Pancreatic Cancer

China
Luo Cong

Completed

Machine Learning for Recurrence Risk of Pancreatic Cancer After Radical Resection (PaC)

Pancreatic Cancer

China
Wen Luo

Completed

Clinical and Radiographic Evaluation of a Cross-shaped Incision Technique

Thin Gingiva | Implant | Clinical and Radiographic Effect | Thick-gingiva

China
Luo yanrong

Completed

Different Chemotherapy Protocols Combined With Intensity Modulated Radiation Therapy in Patients With Locally Advanced Nasopharyngeal Carcinoma

Drug-Related Side Effects and Adverse Reactions

China
Wei LUO

Unknown

Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis

Nasopharyngeal Cancers

China
Pinggu Hospital of Beijing Traditional Chinese...
Pinggu huangsongyu Community hospital; Pinggu Xiagezhuang Community hospital

Recruiting

Effectiveness of Acupuncture for Cyclical Mastalgia （CM）

Mastalgia

China
Linyi People's Hospital

Completed

Effectiveness of Platelet Rich Plasma in Wound Healing

Impacted Third Molar Tooth
Zhang Xiangyu

Completed

The Effect of External Diaphragmatic Pacemaker on the Patients With Chronic Cor Pulmonale

Chronic Cor Pulmonale

China
Linyi People's Hospital

Completed

Long-term Efficacy and Safety Research of Left Bundle Branch Pacing

Atrioventricular Block | Left Bundle Branch Pacing

China
Prevent Age Resort "Pervaya Liniya"

Recruiting

First Line Prevent Age Study (FLIPS)

Healthy Aging | Healthy Diet | Healthy Lifestyle

Russian Federation
He Huang
Lingyi Biotech Co., Ltd.

Recruiting

A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I (LY-M001)

Gaucher Disease Type I

China
Zhejiang Xingyue Biotechnology Co., Ltd.

Completed

Evaluation of HQ® Matrix Medical Wound Dressing for Healing of Donor Site Wounds

Donor Site Wound

China
Qingyun Yin

Unknown

Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia (TAAS)

Schizophrenia

China
Yingu Pharmaceutical Co., Ltd

Active, not recruiting

Study of Bencycloquidium Bromide Nasal Spray in the Treatment of Moderate-severe Persistent Allergic Rhinitis

Allergic Rhinitis

China
LEO Pharma

Recruiting

Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema (DELTA TEEN)

Chronic Hand Eczema

Spain, France, Belgium, Australia, Canada, Poland, United Kingdom
LEO Pharma

Recruiting

Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight (ADJUST)

Psoriasis Vulgaris

Belgium, Italy, Spain, Germany, Czechia, Greece, United Kingdom, France, Hungary, Poland, Netherlands
LEO Pharma

Active, not recruiting

Investigating the Safety of LEO 158968 in Healthy Volunteers

Healthy Volunteers

Netherlands
LEO Pharma

Completed

A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis

Stable Plaque Psoriasis

China
LEO Pharma

Active, not recruiting

Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

Atopic Dermatitis

United States, Belgium, Canada, Czechia, France, Germany, Italy, Japan, Poland, Spain, United Kingdom
LEO Pharma

Terminated

Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab (COBRA)

Psoriasis | Plaque Psoriasis | Psoriasis Vulgaris

Belgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
LEO Pharma

Completed

Tralokinumab Administered With Device A in Adults and Adolescents With Moderate-to-severe Atopic Dermatitis (INJECZTRA)

Atopic Dermatitis

United States
LEO Pharma

Completed

An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

Atopic Dermatitis

United States, Canada, Germany, Poland
LEO Pharma

Completed

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

Atopic Dermatitis

United States, Belgium, Canada, Australia, France, Germany, Japan, Netherlands, Poland, United Kingdom
LEO Pharma

Completed

Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema

Chronic Hand Eczema

Germany
LEO Pharma

Completed

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5) (ECZTRA 5)

Atopic Dermatitis

United States, Canada
LEO Pharma

Completed

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

Atopic Dermatitis

United States
LEO Pharma

Completed

Tacrolimus Blood Levels After Topical Application of Tacrolimus on Healthy Skin

Healthy

Germany
LEO Pharma

Completed

A Trial to Evaluate the Effect of Delgocitinib on the Heart Rhythm of Healthy People

Healthy Volunteers

United Kingdom
LEO Pharma

Terminated

Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis

Disseminated Intravascular Coagulation
LEO Pharma

Completed

Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib Cream

Healthy Volunteers

Germany
LEO Pharma

Completed

Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis

Actinic Keratosis

United States
LEO Pharma

Completed

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

Chronic Hand Eczema

United States, Germany, Denmark
LEO Pharma

Completed

Body PSOriasis: Long-term Relapse CONTROL (PSO-CONTROL)

Psoriasis Vulgaris

Russian Federation
LEO Pharma

Completed

Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis

Atopic Dermatitis

United Kingdom
LEO Pharma

Completed

Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream

Healthy Volunteers

Germany
LEO Pharma

Completed

Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.

Psoriasis Vulgaris

Germany
LEO Pharma

Completed

LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris

Psoriasis Vulgaris

United States, Canada, Germany, United Kingdom, France, Poland
LEO Pharma

Completed

Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE) (PREDICARE)

Venous Thromboembolism

France
LEO Pharma

Completed

LEO 29102 Cream in the Treatment of Atopic Dermatitis

Atopic Dermatitis

Canada, Finland, Germany
LEO Pharma

Completed

LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

United States
LEO Pharma

Completed

A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People

Healthy

United Kingdom
LEO Pharma

Completed

Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

Actinic Keratosis

United States, Canada
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up

Actinic Keratosis

United States
LEO Pharma

Completed

Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions

Actinic Keratosis

United States

3

Subscribe